Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 902 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 20, 2026, 1:03 PM EDT
Not listed Not applicable Interventional

Zypan Functional Dyspepsia

NCT06320379
View directory record Official record
Conditions
Dyspepsia
Interventions
Zypan, Placebo Comparator
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT03546907
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 75 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strawberry Consumption in Overweight and Obese Individuals

NCT04094103
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Active strawberry powder, Placebo strawberry powder, Mixed strawberry powder
Dietary Supplement
Lead sponsor
Carl Ade, M.S., Ph.D.
Other
Eligibility
35 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 20, 2026, 1:03 PM EDT
Terminated Phase 3 Interventional Results available

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
16
States / cities
Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 1:03 PM EDT
Active, not recruiting Not applicable Interventional

Myo-Inositol for Infertility in PCOS

NCT04407754
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Inositol supplement, Placebo supplement
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 36 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Strawberry Consumption on the Microbiome

NCT04217122
View directory record Official record
Conditions
Microbiome
Interventions
strawberry powder, placebo powder
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Circadian Modulation of Grape Consumption and Oxidative Stress Response

NCT05873530
View directory record Official record
Conditions
Oxidative Stress
Interventions
Grape
Other
Lead sponsor
Idaho State University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pocatello, Idaho
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nitrate Supplementation and Muscle Blood Flow

NCT03459027
View directory record Official record
Conditions
Vasodilation, Blood Pressure, Active Hyperemia, Aging
Interventions
Super Beets, Beetroot powder
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
60 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

NCT01682837
View directory record Official record
Conditions
Hypertension
Interventions
Potassium chloride powder, Potassium citrate powder, Potassium magnesium citrate powder, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

NCT01124422
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 20, 2026, 1:03 PM EDT
Not yet recruiting Phase 2 Interventional

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC)
Drug · Other
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01543828
View directory record Official record
Conditions
COPD
Interventions
indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans

NCT02472171
View directory record Official record
Conditions
Inflammation
Interventions
High saturated fat meal, placebo powder and sunflower oil, High saturated fat meal, blueberry powder and sunflower oil, High saturated fat meal, placebo powder and DHA
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 20, 2026, 1:03 PM EDT
Not listed Not applicable Interventional

Investigation of Supplemental L-alanine in the Management of Dietary Fructose Intolerance

NCT04022434
View directory record Official record
Conditions
Fructose Intolerance
Interventions
Placedo, Alanine
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Urinary Track Infection Prevention After Urogynecological Surgery

NCT03818321
View directory record Official record
Conditions
Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
Interventions
Methenamine Hippurate 1 g tablet, Placebo tablet
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

NCT00396877
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel (SR25990), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 92 Days
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 20, 2026, 1:03 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713
View directory record Official record
Conditions
Chronic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 1:03 PM EDT
Withdrawn Phase 2 Interventional

Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

NCT01858480
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
D-ribose, Placebo
Drug · Other
Lead sponsor
RiboCor, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
20
States / cities
Long Beach, California • Modesto, California • Sylmar, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hemp Fiber Ingestion and Gut Permeability After Exercise

NCT06204666
View directory record Official record
Conditions
Gastrointestinal Dysfunction, Metabolic Disturbance
Interventions
High Dose Hemp Fiber Bar, Low Dose Hemp Fiber Bar, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 20, 2026, 1:03 PM EDT
Recruiting Phase 2 Interventional

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

NCT06018766
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Interventions
LAM-001, Placebo
Drug
Lead sponsor
Steven Hays, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

ERG/5-HTP in Fragile X Syndrome (FXS)

NCT05030129
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
5-Hydroxytryptophan, Ergoloid Mesylates, Matching placebo for Ergoloid mesylates, Matching placebo for 5-Hydroxytryptophan
Drug
Lead sponsor
Elizabeth Berry-Kravis
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

NCT01154101
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
St Louis, Missouri • New York, New York • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 20, 2026, 1:03 PM EDT